IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differentiation and maturation of the malignant clone targeting IDH is an emerging strategy to promote clinical responses in AML. Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively enasidenib and ivosidenib. In this review, the contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML will be highlighted.

Original languageEnglish (US)
Article number639387
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - Mar 29 2021
Externally publishedYes

Keywords

  • AML
  • IDH
  • acute myeloid leukemia
  • enasidenib
  • isocitrate dehydrogenase
  • ivosidenib
  • target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'IDH1/IDH2 Inhibition in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this